|
1
|
Amiri-Kordestani L, Basseville A, Kurdziel
K, Fojo AT and Bates SE: Targeting MDR in breast and lung cancer:
Discriminating its potential importance from the failure of drug
resistance reversal studies. Drug Resist Updat. 15:50–61. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Muramatsu T: Basigin (CD147), a
multifunctional transmembrane glycoprotein with various binding
partners. J Biochem. 159:481–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Somno A, Anuchapreeda S, Chruewkamlow N,
Pata S, Kasinrerk W and Chiampanichayakul S: Involvement of CD147
on multidrug resistance through the regulation of P-glycoprotein
expression in K562/ADR leukemic cell line. Leuk Res Rep. 6:33–38.
2016.PubMed/NCBI
|
|
4
|
Zhou S, Liao L, Chen C, Zeng W, Liu S, Su
J, Zhao S, Chen M, Kuang Y, Chen X and Li J: CD147 mediates
chemoresistance in breast cancer via ABCG2 by affecting its
cellular localization and dimerization. Cancer Lett. 337:285–292.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan Y, He B, Song G, Bao Q, Tang Z, Tian F
and Wang S: CD147 silencing via RNA interference reduces tumor cell
invasion, metastasis and increases chemosensitivity in pancreatic
cancer cells. Oncol Rep. 27:2003–2009. 2012.PubMed/NCBI
|
|
6
|
Xu BQ, Fu ZG, Meng Y, Wu XQ, Wu B, Xu L,
Jiang JL, Li L and Chen ZN: Gemcitabine enhances cell invasion via
activating HAb18G/CD147-EGFR-pSTAT3 signaling. Oncotarget.
7:62177–62193. 2016.PubMed/NCBI
|
|
7
|
Kono K, Iinuma H, Akutsu Y, Tanaka H,
Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R,
et al: Multicenter, phase II clinical trial of cancer vaccination
for advanced esophageal cancer with three peptides derived from
novel cancer-testis antigens. J Transl Med. 10:1412012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki H, Fukuhara M, Yamaura T, Mutoh S,
Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, et
al: Multiple therapeutic peptide vaccines consisting of combined
novel cancer testis antigens and anti-angiogenic peptides for
patients with non-small cell lung cancer. J Transl Med. 11:972013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsang KY, Fantini M, Fernando RI, Palena
C, David JM, Hodge JW, Gabitzsch ES, Jones FR and Schlom J:
Identification and characterization of enhancer agonist human
cytotoxic T-cell epitopes of the human papillomavirus type 16
(HPV16) E6/E7. Vaccine. 35:2605–2611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Colella TA, Bullock TN, Russell LB,
Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP and
Engelhard VH: Self-tolerance to the murine homologue of a
tyrosinase-derived melanoma antigen: Implications for tumor
immunotherapy. J Exp Med. 191:1221–1232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen H, Shao HW, Chen XH, Wu FL, Wang H,
Huang ZL, Shen J, Wang T, Zhang WF and Huang SL: Identification of
a novel HLA-A2-restricted mutated Survivin epitope and induction of
specific anti-HCC CTLs that could effectively cross-recognize
wild-type Survivin antigen. Cancer Immunol Immunother. 62:393–403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shao H, Lin Y, Wang T, Ou Y, Shen H, Tao
C, Wu F, Zhang W, Bo H, Wang H and Huang S: Identification of
peptide-specific TCR genes by in vitro peptide stimulation and CDR3
length polymorphism analysis. Cancer Lett. 363:83–91. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Zou L, Zhou D, Zhou Z, Tang F, Xu
Z and Liu X: Overexpression of ubiquitin carboxyl terminal
hydrolase-L1 enhances multidrug resistance and invasion/metastasis
in breast cancer by activating the MAPK/Erk signaling pathway. Mol
Carcinog. 55:1329–1342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rammensee HG, Bachmann J, Emmerich NP,
Bachor OA and Stevanović S: SYFPEITHI: Database for MHC ligands and
peptide motifs. Immunogenetics. 50:213–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nijman HW, Houbiers JG, Vierboom MP, van
der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ and
Kast WM: Identification of peptide sequences that potentially
trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol.
23:1215–1219. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wijdeven RH, Pang B, Assaraf YG and
Neefjes J: Old drugs, novel ways out: Drug resistance toward
cytotoxic chemotherapeutics. Drug Resist Updat. 28:65–81. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curiel TJ: Immunotherapy: A useful
strategy to help combat multidrug resistance. Drug Resist Updat.
15:106–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Toole BP and Slomiany MG: Hyaluronan, CD44
and Emmprin: Partners in cancer cell chemoresistance. Drug Resist
Updat. 11:110–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Walter M, Simanovich E, Brod V, Lahat N,
Bitterman H and Rahat MA: An epitope-specific novel anti-EMMPRIN
polyclonal antibody inhibits tumor progression. Oncoimmunology.
5:e10780562015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tourdot S, Scardino A, Saloustrou E, Gross
DA, Pascolo S, Cordopatis P, Lemonnier FA and Kosmatopoulos K: A
general strategy to enhance immunogenicity of low-affinity
HLA-A2.1-associated peptides: Implication in the identification of
cryptic tumor epitopes. Eur J Immunol. 30:3411–3421. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engels B, Engelhard VH, Sidney J, Sette A,
Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA and Schreiber
H: Relapse or eradication of cancer is predicted by peptide-major
histocompatibility complex affinity. Cancer Cell. 23:516–526. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Valmori D, Fonteneau JF, Lizana CM,
Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini
JC and Romero P: enhanced generation of specific tumor-reactive ctl
in vitro by selected melan-a/mart-1 immunodominant peptide
analogues. J Immunol. 160:1750–1758. 1998.PubMed/NCBI
|
|
24
|
Slansky JE, Rattis FM, Boyd LF, Fahmy T,
Jaffee EM, Schneck JP, Margulies DH and Pardoll DM: Enhanced
antigen-specific antitumor immunity with altered peptide ligands
that stabilize the MHC-peptide-TCR complex. Immunity. 13:529–538.
2000. View Article : Google Scholar : PubMed/NCBI
|
